Silmitasertib
Silmitasertib is the first selective, orally available CK2 inhibitor to enter clinical trials. CK2 is a constitutively active serine/threonine kinase that phosphorylates over 300 substrates including PTEN, p21, and caspase-3, promoting survival and suppressing apoptosis. Active in haematological malignancies and cholangiocarcinoma; CK2 inhibition also augments immune activation by promoting type I interferon signalling.
Description
Scientific Overview: Silmitasertib is the first selective, orally available CK2 inhibitor to enter clinical trials. CK2 is a constitutively active serine/threonine kinase that phosphorylates over 300 substrates including PTEN, p21, and caspase-3, promoting survival and suppressing apoptosis. Active in haematological malignancies and cholangiocarcinoma; CK2 inhibition also augments immune activation by promoting type I interferon signalling.
Mechanism of Action: CK2 (Casein Kinase 2) Inhibitor
Purity: ≥99% | Molecular Formula: C20H14ClN3O2
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | CK2 (Casein Kinase 2) Inhibitor |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C20H14ClN3O2 |
| CAS Number | 1009820-21-6 |
